ERBB2 and non-small cell lung carcinoma: We demonstrated anti-proliferative effects with the combination of LOR and SAP inhibitors in EML4-ALK+harbouring NSCLC cells, resulting in a significant loss of ERBB2, ERBB3, and subsequently, loss of PI3K/AKT and RAS/MAPK signalling pathways.